Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease

• Published in: Scientific reports Vol. 8; no. 1; pp. 17368 - 8
• Main Authors: Lin, Yung-Shuan, Lee, Wei-Ju, Wang, Shuu-Jiun, Fuh, Jong-Ling
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 26.11.2018; Nature Publishing Group
• Subjects: 13; 13/56; 631/378/2611; 631/378/2612; 692/617/375/132/1283; Aged; Alzheimer Disease - blood; Alzheimer Disease - metabolism; Alzheimer Disease - physiopathology; Alzheimer's disease; Amyloid beta-Peptides - metabolism; Biomarkers; Biomarkers - blood; Cognition - physiology; Cognitive ability; Cognitive Dysfunction - blood; Cognitive Dysfunction - metabolism; Dementia; Dementia disorders; Female; Humanities and Social Sciences; Humans; Intermediate Filaments - metabolism; Male; Measuring techniques; Movement disorders; multidisciplinary; Neurodegeneration; Neurodegenerative diseases; Neurofilament Proteins - blood; Neurofilament Proteins - metabolism; Neuropsychological Tests; Parkinson Disease - blood; Parkinson Disease - metabolism; Parkinson Disease - physiopathology; Parkinson's disease; Plasma; Plasma - metabolism; Psychology; Science; Science (multidisciplinary); Sensitivity and Specificity; Neurofilament Light Chain; Parkinsonian Disorders; Mild Cognitive Impairment (MCI); Blood-based Biomarkers; Category Verbal Fluency
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-018-35766-w

Plasma neurofilament light (NFL) has been proposed as a blood-based biomarker for neurodegeneration in Alzheimer’s disease (AD) and parkinsonian disorders. However, the relationship between plasma NFL and cognitive decline in dementia due to Parkinson’s disease (PD) remains to be elucidated. In this research, 119 AD, 56 mild cognitive impairment (MCI), 26 non-demented PD (PDND), and 23 Parkinson’s disease dementia (PDD) patients, as well as 59 cognitively healthy controls (HC) were recruited. Each subject underwent a battery of neuropsychological testing. Plasma NFL levels were measured in duplicate using an NF-Light assay and transferred onto the Simoa platform with a home-brew kit. Plasma NFL was significantly increased in the AD group, compared with the control, MCI, PDND, and PDD groups. Plasma NFL was significantly higher in the PDD group, compared with the PDND group. High plasma NFL correlated with poor cognition in AD and PD, but not with motor symptoms in PD. Plasma NFL may represent a biomarker of cognitive decline in AD and PD, with more specificity for AD.